ema prac naion semaglutide june 2025 A potentially blinding condition is a very rare side effect of the GLP-1 receptor agonist (Ozempic, Wegovy, Rybelsus), the European Medicines Agency (EMA) concluded. https://www.medpagetoday.com/ophthalmology/generalophthalmology/115938?trw=no Meeting highlights from the Pharmacovigilance

Users should be cautious of gallbladder problems, weight loss benefits, and potential risks like pancreatitis, low blood sugar, and allergic reactions

Pale yellow to light straw indicates adequate hydration

Aging Brain: Glutathione levels decline with age, particularly in the central nervous system, which may increase susceptibility to degenerative processes and oxidative injury after stroke or other insults

Ozempic wasnt the first GLP-1 agonist on the market, but its probably the most well-known

This cross-talk means your weight loss response may differ from patients with intact gallbladders, which is why personalized dosing matters

Im really digging the template/theme of this blog